Define AD agitation and psychosis, and describe their prevalence and clinical significance Implement strategies for timely, accurate recognition and assessment of AD agitation and psychosis Evaluate the MOAs, recent clinical evidence, and potential therapeutic implications associated with novel and emerging agents for AD agitation and psychosis
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedDec 12, 2025
-
Last day to claim creditDec 12, 2026 2 months left
-
HMP Education Architecture of Agitation: Pathophysiology of Agitation in Alzheimer’s Disease and Emerging Treatments
-
HMP Education New Solutions for Excessive Daytime Sleepiness and Obstructive Sleep Apnea: The Silent Killer of Better Outcomes in Psychiatric Practice
-
HMP Education Antidepressants for Older Adults with MDD: Integrating Clinical and Real-World Evidence with Patient-Specific Considerations to Optimize Outcomes
